{
  "main_header": {
    "sid": 1002854,
    "name": "Vanta Bioscience",
    "stock_name": "Vanta Bioscience",
    "full_name": "Vanta Bioscience Ltd",
    "name_url": "stocks-analysis/vanta-bioscience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "21.45",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "21.45",
    "mcapval": "16.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540729,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 67,
    "indexname": "",
    "isin": "INE695X01011",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.5 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vanta-bioscience-1002854-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Vanta Bioscience?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-vanta-bioscience-3703961",
        "imagepath": "",
        "date": "2025-11-15 00:20:07",
        "description": "Answer:\nThe historical performance of Vanta Bioscience has shown significant fluctuations over the years, particularly in net sales and profitability. In March 2025, net sales dropped to 1.96 Cr from 9.72 Cr in March 2024, which was a decrease from 6.28 Cr in March 2023 and 9.69 Cr in March 2022. The total operating income followed a similar trend, declining from 9.72 Cr in March 2024 to 1.96 Cr in March 2025. The company has faced increasing total expenditure, which reached 6.22 Cr in March 2025, compared to 8.41 Cr in March 2024. This led to an operating profit (PBDIT) of -4.15 Cr in March 2025, a stark contrast to the positive 1.42 Cr in March 2024. Profit before tax also worsened, recording -4.11 Cr in March 2025, down from -2.54 Cr in March 2024. Consequently, the profit after tax for March 2025 was -4.77 Cr, worsening from -2.32 Cr in March 2024. The company's earnings per share (EPS) reflected this d..."
      }
    ],
    "total": 17,
    "sid": "1002854",
    "stock_news_url": "https://www.marketsmojo.com/news/vanta-bioscience-1002854"
  },
  "announcements": [
    {
      "caption": "Financial Results For The Half Year Ended September 30 2025",
      "datetime": "14-Nov-2025",
      "details": "Financial results for the half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14 2025",
      "datetime": "14-Nov-2025",
      "details": "Outcome of the Board Meeting held on November 14 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Board Meeting To Be Held On 14.11.2025",
      "datetime": "08-Nov-2025",
      "details": "Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the Unaudited financial results of the Company for the half year ended September 30 2025 and to take note of the limited review report of the statutory auditors thereon.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Vanta Bioscience?

2025-11-15 00:20:07

Answer: The historical performance of Vanta Bioscience has shown significant fluctuations over the years, particularly in net sales and profitability. In March 2025, net sales dropped to 1.96 Cr from 9.72 Cr in March 2024, which was a decrease from 6.28 Cr in March 2023 and 9.69 Cr in March 2022. The total operating income followed a similar trend, declining from 9.72 Cr in March 2024 to 1.96 Cr in March 2025. The company has faced increasing total expenditure, which reached 6.22 Cr in March 2025, compared to 8.41 Cr in March 2024. This led to an operating profit (PBDIT) of -4.15 Cr in March 2025, a stark contrast to the positive 1.42 Cr in March 2024. Profit before tax also worsened, recording -4.11 Cr in March 2025, down from -2.54 Cr in March 2024. Consequently, the profit after tax for March 2025 was -4.77 Cr, worsening from -2.32 Cr in March 2024. The company's earnings per share (EPS) reflected this d...

Read More

View All News